Do Ozempic and Weight-Loss Injections Cause Bone Loss? A UK Evidence Guide

Do Ozempic and weight-loss injections cause bone loss?

Short answer: they can cause a modest drop in bone mineral density — but the best current evidence suggests this is driven by the rapid weight loss itself, not by the medication directly. Whenever the body loses a large amount of weight quickly — through dieting, surgery or medication — some bone and muscle is lost alongside the fat. GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) appear to follow this same pattern rather than poisoning bone tissue.

A 2025 review in Osteoporosis International concluded that the bone changes seen with GLP-1 medications are modest and resemble those caused by calorie restriction, with bone turnover shifting slightly towards resorption — the same response the skeleton makes to any meaningful weight loss.

Is it the drug or the weight loss damaging my bones?

It's mostly the weight loss. Bone is living tissue that adapts to the load placed on it. When you lose weight rapidly, three things happen at once:

• Less mechanical loading — lighter bodies place less force through the skeleton, so bone is signalled to remodel down.
• Muscle loss — losing lean mass reduces the pull of muscle on bone, a key stimulus for bone strength.
• Nutritional gaps — appetite suppression can mean less protein, calcium and vitamin D at the very moment bone needs them.

This matters because it means the bone loss is largely preventable with the right support — something a drug-versus-no-drug debate misses.

How much bone density do you actually lose?

In a 2024 phase 2 randomised trial published in eClinicalMedicine (The Lancet group), once-weekly semaglutide modestly lowered bone mineral density at the lumbar spine and total hip compared with placebo over 52 weeks, and raised a marker of bone breakdown. The effect was measurable but not dramatic, and varies considerably between individuals.

The practical takeaway is not the exact percentage — it's that the change is real, gradual, and detectable on a scan before it becomes a problem.

Do weight-loss injections increase your risk of osteoporosis or fractures?

This is where the headlines and the evidence diverge — so here is the balanced picture.

On the reassuring side: pooled analyses of large randomised trials in people with type 2 diabetes have generally found GLP-1 medications are associated with no increase, and possibly a reduction, in fracture risk (2018 network meta-analysis of randomised trials).

On the cautious side: some recent observational and conference-presented data have suggested a small increase in osteoporosis diagnoses among GLP-1 users. This evidence is preliminary, observational, and confounded by the fact that people using these drugs differ from those who don't — it should not be read as proof of harm.

Does Mounjaro (tirzepatide) affect bones and muscle differently?

All weight-loss injections cause some loss of lean mass, but the proportion varies. In the SURMOUNT-1 body-composition substudy, roughly three-quarters of the weight lost on tirzepatide was fat and about a quarter was lean (muscle) mass — a similar split to placebo, suggesting preferential fat loss. A 2025 systematic review likewise found tirzepatide largely preserves muscle relative to total weight lost.

Because muscle and bone work together, protecting one helps protect the other — which is why the prevention advice below targets both.

How can you protect your bones on Ozempic, Wegovy or Mounjaro?

The single most powerful protective factor in the research is exercise. In a 2024 JAMA Network Open secondary analysis, participants were split into exercise alone, GLP-1 drug alone, or both. Despite similar weight loss, the drug-alone group lost bone density at the hip and spine, while exercise — alone or combined with the drug — preserved it.

In practice, that means:

• Resistance training (weights, bands, bodyweight) 2–3 times a week to load muscle and bone.
• Weight-bearing activity — walking, stairs, dancing.
• Adequate protein to defend lean mass during weight loss.
• Calcium and vitamin D sufficiency.
• A baseline bone scan so you have something to measure progress against.

Should you get a bone density scan before and during treatment?

If you're over 40, post-menopausal, or already have low bone density, a baseline scan before or early in treatment is a sensible precaution — because there is currently no routine NHS bone-monitoring programme for people on weight-loss injections. That gap means most people lose bone silently, with no way of knowing until a problem appears.

A baseline scan answers the only question that really matters: is my bone density changing, and do I need to act? Because the changes are gradual, catching them early is exactly when prevention works best.

Why a radiation-free REMS scan suits repeat monitoring

Standard DEXA scans use a small dose of X-ray radiation, which makes frequent re-scanning less ideal. REMS (Radiofrequency Echographic Multi Spectrometry) is radiation-free, so it can be repeated safely across a one- or two-year course of treatment to track change over time — which is precisely what monitoring on a weight-loss injection calls for.

You can book a radiation-free bone health assessment or read more about our bone health assessment and where we screen across the UK.

Is bone loss reversible after stopping?

Bone responds to load and nutrition throughout life, so much of the weight-loss-related bone change can be stabilised or partly recovered by maintaining muscle, staying active and eating well — particularly once weight stabilises. The key is knowing where you stand, which is what regular screening provides.

---

This article is part of our weight-loss medications and bone health series. If you're navigating menopause as well, see our menopause and bone health guides.